{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T16:00:31Z","timestamp":1764086431854,"version":"3.45.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":382,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"This article received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunotherapy with programmed cell death 1 (PD-1) checkpoint inhibitors combined with chemoradiotherapy shows great potential for cancer treatment and is getting extensively researched. However, a plethora of immune-related adverse events (irAEs) has been observed during anti-PD-1 treatment, including cutaneous adverse events, such as vitiligo and pruritus. These adverse events may lead to treatment discontinuation. When anti-PD-1 treatment is combined with radiotherapy (RT), irAEs may be exacerbated. Here we present a case report of an elderly patient with stage IIIb rectal cancer, who developed PD-1 inhibitor-associated vitiligo. After a session of RT, vitiligo lesions enlarged shortly thereafter. After discontinuation of anti-PD-1 treatment, vitiligo lesions and pruritus quickly improved with appropriate treatment. The rectal cancer achieved clinical complete response with no sign of recurrence or metastasis during follow-up. Considering the similar mechanism of anti-PD-1 treatment in targeting cancer and in inducing irAEs, cutaneous adverse events may be associated with favourable clinical response. Additionally, cutaneous irAEs aggravated by RT in this patient may suggested significant immune activation, which may occasionally contribute to tumour regression and favourable clinical outcome.<\/jats:p>","DOI":"10.1002\/ski2.287","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T07:57:45Z","timestamp":1695715065000},"source":"Crossref","is-referenced-by-count":1,"title":["Radiotherapy May Exacerbated Anti-Programmed Cell Death 1 Treatment Induced Vitiligo: A Case Report"],"prefix":"10.1093","volume":"4","author":[{"given":"Chengqian","family":"Chen","sequence":"first","affiliation":[{"name":"Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qihang","family":"Chang","sequence":"additional","affiliation":[{"name":"Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Michigan , Ann Arbor ,, Michigan ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai ,","place":["China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fudan University Shanghai Cancer Center , Shanghai ,","place":["China"]},{"name":"Department of Oncology, Shanghai Medical College, Fudan University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0722-1274","authenticated-orcid":false,"given":"Xiuli","family":"Wang","sequence":"additional","affiliation":[{"name":"Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University , Shanghai ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"issue":"5","key":"2025112510513270600_ski2287-bib-0001","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"2025112510513270600_ski2287-bib-0002","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"23","key":"2025112510513270600_ski2287-bib-0003","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/nejmoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andre","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"2025112510513270600_ski2287-bib-0004","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/pcmr.12701","article-title":"Regulation of melanocyte stem cell behavior by the niche microenvironment","volume":"31","author":"Li","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"issue":"4","key":"2025112510513270600_ski2287-bib-0005","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/med.21426","article-title":"Trends in regenerative medicine: repigmentation in vitiligo through melanocyte stem cell mobilization","volume":"37","author":"Birlea","year":"2017","journal-title":"Med Res Rev"},{"issue":"8","key":"2025112510513270600_ski2287-bib-0006","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/exd.14155","article-title":"Hair follicle immune privilege and its collapse in alopecia areata","volume":"29","author":"Bertolini","year":"2020","journal-title":"Exp Dermatol"},{"key":"2025112510513270600_ski2287-bib-0007","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"issue":"1","key":"2025112510513270600_ski2287-bib-0008","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3322\/caac.21358","article-title":"Radiotherapy combination opportunities leveraging immunity for the next oncology practice","volume":"67","author":"Herrera","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2025112510513270600_ski2287-bib-0009","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/imr.12573","article-title":"Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences","volume":"280","author":"Brix","year":"2017","journal-title":"Immunol Rev"},{"issue":"11","key":"2025112510513270600_ski2287-bib-0010","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2025112510513270600_ski2287-bib-0011","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.ccr-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025112510513270600_ski2287-bib-0012","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/1346-8138.14805","article-title":"Efficacy of combined radiotherapy and anti-programmed death 1 therapy in acral and mucosal melanoma","volume":"46","author":"Kato","year":"2019","journal-title":"J Dermatol"},{"key":"2025112510513270600_ski2287-bib-0013","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6631643","article-title":"Combination of immune checkpoint inhibitors and radiotherapy for advanced non-small-cell lung cancer and prostate cancer: a meta-analysis","volume":"2021","author":"Xu","year":"2021","journal-title":"J Oncol"},{"key":"2025112510513270600_ski2287-bib-0014","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000106412","article-title":"Vitiligo","volume":"35","author":"Matz","year":"2007","journal-title":"Curr Probl Dermatol"},{"issue":"1","key":"2025112510513270600_ski2287-bib-0015","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0749.1994.tb00013.x","article-title":"Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo","volume":"7","author":"Abdel-Naser","year":"1994","journal-title":"Pigm Cell Res"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/4\/1\/ski2.287\/59729941\/skinhd_4_1_e287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/4\/1\/ski2.287\/59729941\/skinhd_4_1_e287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:51:38Z","timestamp":1764085898000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/doi\/10.1002\/ski2.287\/7755687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,9,26]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ski2.287","relation":{},"ISSN":["2690-442X"],"issn-type":[{"type":"electronic","value":"2690-442X"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,9,26]]},"article-number":"ski2.287"}}